Harvard Bioscience (HBIO) Cash from Financing Activities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cash from Financing Activities data on file, last reported at -$9000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 99.25% year-over-year to -$9000.0 in Q1 2026; TTM through Mar 2026 was -$96000.0, a 65.71% increase from a year earlier, with the FY2025 full-year figure at -$1.3 million, down 885.5% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$9000.0, down from $2.4 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for HBIO reached as high as $2.4 million in Q4 2025 and fell as low as -$4.1 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged -$964823.5 across 5 years, with a median of -$1.2 million in 2025.
• Across the five-year window, Cash from Financing Activities plunged 3177.66% in 2023 and surged 280.47% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$2.7 million in 2022, then sank by 50.77% to -$4.1 million in 2023, then surged by 67.03% to -$1.4 million in 2024, then jumped by 280.47% to $2.4 million in 2025, then sank by 100.37% to -$9000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$9000.0 in Q1 2026, $2.4 million in Q4 2025, and -$1.3 million in Q3 2025.